Published on 21/12/2025
Innovative Strategies to Identify Undiagnosed Patients for Rare Disease Trials
The Hidden Population: Why Undiagnosed Patients Matter
One of the most significant barriers in rare disease clinical research is the “diagnostic odyssey” — the long, uncertain journey many patients endure before receiving a diagnosis. For some, this process takes years, if not decades. Unfortunately, during this delay, many remain invisible to the clinical research community, missing critical windows for therapeutic intervention.
These undiagnosed individuals represent a vast, untapped population for clinical trials. Engaging them requires innovative, cross-functional strategies that blend data science, community outreach, diagnostic technologies, and healthcare provider education. Doing so not only improves recruitment efficiency but also addresses major equity gaps in rare disease research.
Challenges in Reaching Undiagnosed Rare Disease Populations
Unlike diagnosed patients who may already be in contact with advocacy organizations or registries, undiagnosed individuals typically fall through systemic cracks due to:
- Lack of symptom recognition: Many rare diseases present as common conditions in early stages, leading to misdiagnoses.
- Geographic and socioeconomic barriers: Rural or underserved populations may lack access to specialists or diagnostic tools.
- Stigma and psychological factors: Some families avoid further medical engagement due to fear, cost, or frustration with previous
Overcoming these obstacles requires a proactive, data-driven, and compassionate approach.
Genomic Screening as a Tool for Early Identification
Advances in genomic sequencing now allow for earlier identification of rare genetic diseases—even before symptoms manifest. Population-based genetic screening initiatives can serve dual purposes: early diagnosis and trial enrollment pipelines.
Examples include:
- Newborn screening expansion: Incorporating rare disease panels into state and national newborn screening programs.
- Carrier screening in adults: Offering genetic testing to adults with unexplained chronic symptoms or family history.
- Biobank integration: Mining existing genomic biobanks to identify matches with trial eligibility criteria.
Such efforts must be conducted with robust consent protocols, data governance, and follow-up care plans.
AI-Powered Diagnostic Support for Physicians
Artificial intelligence is increasingly being used to shorten the diagnostic journey. Clinical decision support tools trained on large datasets can analyze symptoms, family history, and laboratory values to flag potential rare conditions.
For example, a machine-learning model deployed in a European healthcare system successfully flagged 78% of undiagnosed Fabry disease cases based on patient history and enzyme testing patterns.
Integrating these tools into electronic health record (EHR) systems enables primary care physicians and general practitioners to trigger specialist referrals sooner — ultimately connecting more patients to research opportunities.
Collaboration with Diagnostic Networks and Genetic Counselors
Another key recruitment approach is to establish partnerships with diagnostic labs, genetic counselors, and centralized referral services. These professionals often encounter undiagnosed patients and can serve as valuable allies in trial outreach.
For instance, in the U.S., programs like Australian New Zealand Clinical Trials Registry list studies where genetic testing is offered as part of the trial. Genetic counselors, with appropriate IRB-approved materials, can introduce these options to eligible families.
Additionally, rare disease diagnostic networks often maintain anonymized data sets that can be queried for recruitment feasibility analyses and geo-targeted outreach planning.
Building Pre-Diagnostic Patient Communities
Many patients with undiagnosed conditions cluster online in communities based on symptoms rather than named diseases. These platforms—like Reddit threads, Facebook groups, or standalone forums—can be approached respectfully and ethically for awareness-building:
- Share general information about the importance of rare disease research and early diagnosis
- Post links to observational registries or IRB-approved interest forms
- Collaborate with moderators to host AMA (Ask Me Anything) sessions with clinicians
These communities often express a deep desire to be heard and validated, making them more receptive to research engagement when approached correctly.
Case Example: Targeted Outreach for Undiagnosed Neurodevelopmental Disorders
A biotech firm targeting a rare X-linked neurodevelopmental disorder created a multi-pronged campaign to identify undiagnosed individuals:
- Partnered with pediatric neurologists to share educational packets
- Created a symptom checker app integrated with ICD-10 filters
- Launched Google and Facebook ads targeting caregiver search behavior patterns
- Offered free genetic screening kits via an IRB-approved portal
In six months, the campaign resulted in:
- 1,500 pre-screenings completed
- 213 genetically confirmed diagnoses
- 47 trial participants enrolled, contributing to full study completion
Conclusion: From the Unseen to the Enrolled
Reaching undiagnosed populations is essential for advancing rare disease research. Through a mix of technology, clinical collaboration, ethical outreach, and patient empowerment, sponsors can uncover new participants hiding in plain sight.
These efforts not only improve trial feasibility but can also bring hope and clarity to individuals and families who have searched for answers for years. For rare disease sponsors, targeting the undiagnosed isn’t just a recruitment tactic—it’s a mission-driven responsibility.